[EN] SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES [FR] DÉRIVÉS DE SULFONAMIDE DE LA BENZYLAMINE POUR LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL (SNC)
摘要:
苯甲胺的磺胺基衍生物的化学式(I),其中A代表未取代或取代的苯基;或9-或10-成员的双环族,通过其中一个芳香碳原子连接到-(O) x - (CH 2 ) y -,由苯环与含有1个或2个杂原子(从N和O组成的组中独立选择)的-成员杂芳环融合而成,其中该双环族未取代或取代,或与含有1个或2个O原子的5-或6-成员非芳杂环取代,其中杂环未取代或取代为一个或多个C1 -C3 -烷基;D代表从中选择的一组:未取代或取代的苯基;未取代或取代的萘基;未取代或取代的噻吩基;由咪唑环融合而成的5-成员非芳碳环的双环族;由苯环融合而成的含有1个或2个杂原子(从N、O和S组成的组中独立选择)的5-成员杂芳环的双环族,未取代或取代,并通过苯环的一个碳原子与磺胺基团连接;以及由苯环融合而成的5-或6-成员非芳杂环的双环族,其中杂原子独立选择自N和O组成的组,未取代或取代,并通过苯环的一个碳原子与磺胺基团连接;R代表H或-CH 3;x为0或1;y为2或3;以及其药学上可接受的盐和溶剂化合物,但是如果x为0且y为2,则D为未取代或取代的萘基且带有一个卤原子,如果R代表-CH 3,则A不是未取代或取代的苯基。这些化合物可用于治疗和/或预防中枢神经系统疾病。
[EN] SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES<br/>[FR] DÉRIVÉS DE SULFONAMIDE DE LA BENZYLAMINE POUR LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL (SNC)
申请人:ADAMED SP ZOO
公开号:WO2013140347A1
公开(公告)日:2013-09-26
Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted;or 9-or 10-membered bicyclic group, linked to –(O) x - (CH 2 ) y -through one of its aromatic carbon atoms,consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5-or 6-membered non-aromaticheterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C1 -C3 - alkyls; D represents a group selected from:phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted;thiophene unsubstituted or substituted;bicyclic group consisting of imidazolering fused with5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring;and bicyclic group consisting of benzene ring fused with -or 6-membered non-aromatic heterocyclic ring having 1 or 2heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon atoms of benzene ring;R represents H or –CH 3;x is 0 or 1;yis 2 or 3;and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents –CH 3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders.
苯甲胺的磺胺基衍生物的化学式(I),其中A代表未取代或取代的苯基;或9-或10-成员的双环族,通过其中一个芳香碳原子连接到-(O) x - (CH 2 ) y -,由苯环与含有1个或2个杂原子(从N和O组成的组中独立选择)的-成员杂芳环融合而成,其中该双环族未取代或取代,或与含有1个或2个O原子的5-或6-成员非芳杂环取代,其中杂环未取代或取代为一个或多个C1 -C3 -烷基;D代表从中选择的一组:未取代或取代的苯基;未取代或取代的萘基;未取代或取代的噻吩基;由咪唑环融合而成的5-成员非芳碳环的双环族;由苯环融合而成的含有1个或2个杂原子(从N、O和S组成的组中独立选择)的5-成员杂芳环的双环族,未取代或取代,并通过苯环的一个碳原子与磺胺基团连接;以及由苯环融合而成的5-或6-成员非芳杂环的双环族,其中杂原子独立选择自N和O组成的组,未取代或取代,并通过苯环的一个碳原子与磺胺基团连接;R代表H或-CH 3;x为0或1;y为2或3;以及其药学上可接受的盐和溶剂化合物,但是如果x为0且y为2,则D为未取代或取代的萘基且带有一个卤原子,如果R代表-CH 3,则A不是未取代或取代的苯基。这些化合物可用于治疗和/或预防中枢神经系统疾病。
Improved procedure for the reductive phenylation and cyclization of nitroarenes
The reductive phenylation of nitroarenes was improved by using iron pentacarbonyl (IPC) as a reducing reagent. The method was applied to the synthesis of ellipticine and dibenzazocine derivatives.